Guidance for Appendices/User Tables
All Cores
DEFINITIONS
CFAR Beneficiary: An individual who receives assistance of any sort from the CFAR. Not all CFAR
beneficiaries are counted as CFAR users.
CFAR Member: There is no official NIH CFAR definition of a CFAR “member.” Each CFAR should establish
its own criteria for membership in the CFAR.
CFAR User: A CFAR beneficiary who is eligible to serve as PI on any NIH funding mechanism. Only CFAR
Users are counted when filling out Appendix A or sections I.A and I.B in the Director’s Overview.
Categories: All CFAR users will fall into one or more of six categories. All CFAR users will fall into
Categories 1-4. Some CFAR users may also fall into Categories 5-6
NIH AIDS PIs
Category 1
A researcher who is or has ever been PI on an R01 equivalent
grant in HIV/AIDS
NIH PIs being
brought into
AIDS research
Category 2
A researcher who is or has ever been PI on an R01 equivalent
grant, but never in HIV/AIDS
Category 3
NIH “New Investigators,” An NIH definition that encompasses
individuals who have received funding as a PI from NIH*, but not
yet at the R01 equivalent level.
Category 4
CFAR Users who have not yet received funding from NIH* as PI or
Co-PI funding on any NIH grant mechanism
Category 5
Recipients of Core B funding, mentoring, and/or other services
Category 6
Recipients of NIH CFAR administrative supplements
AIDS-research
Pipeline
Developmental
Core Special
Emphasis
*Individuals whose only history of NIH funding at the PI or PD level has come indirectly from NIH, for
example through the CFAR via an NIH CFAR Administrative Supplement, fall into Category 4
Funded Research Base (FRB): The total dollar amount of research funding that the NIH CFAR counts
when determining, during competitive review, whether a given CFAR will receive funding at the Tier 1, Tier 2,
or Tier 3 level. Not all NIH funding mechanisms are included when calculating the FRB and not all projects
funded through allowable mechanisms are eligible for inclusion in a given year’s FRB. See the CFAR PA for
more details.
FRB Project: A project appearing on the “Allow” tab of an FRB Excel spreadsheet. FRB projects are
prioritized for attention from the CFAR.
FRB Report: An Excel spreadsheet provided annually by the NIH CFAR that contains a list of projects that
are counted in a CFAR’s FRB for a given NIH fiscal year.
Percent Use: The percent of a Core’s total time spent on a particular Core Usage table entry (see Appendix
D). Total percent use for a Core should add up to 100%.
Project Period: Five-year increments of funding from NIH. e.g. “3rd” project period.
Rev 10/24/14
1
Project Year: An individual CFAR’s fiscal year, counted from its first year of NIH funding. e.g. YR12 = 12th
year of NIH funding, aka the second year of the third project period, assuming a 5 year D-CFAR project
period.
“R01 Equivalent” Grant: NIH considers the following mechanisms to be “R01 equivalents:”
R01, R23, R29, R37 and, after 2008, DP2. The NIH CFAR also adds “P” series and “U” series to the list.
Reporting Period: The period of time since data for the previous progress report was gathered for
submission, without reference to a CFAR’s fiscal year.
Roles: The types of participation that CFAR users engage in. “CD” (Core Director) and “CU” (Core User) are
standard across all CFARs. For reporting in Appendix A.1 and A.2, each CFAR may define and label
additional roles that best describe their CFAR’s users participation.
Synergy: A “mutually advantageous collaboration between separate entities.” For the purposes of a CFAR
report or application those entities may be two or more separate CFARs (inter-CFAR), two or more Cores
and/or SWGs within the same CFAR (intra-CFAR), or your CFAR and another organization(s) at your
institution or beyond (extra-CFAR).
Value Added: Resources provided by the CFAR that allow an individual or group to accomplish a goal they
otherwise might not be able to accomplish, or simply to accomplish it “better” (more rapidly, more cost
effectively, more collaboratively etc.) than they otherwise might, given the limitations imposed by other NIH
funding mechanisms.
Value Added Activities:
Consultation: Verbal assistance or feedback in a Core faculty member or staff’s area of expertise. For
example, helping to develop or critique a research study design
Equipment/Space:
Shared Equipment: Access to equipment that a Core user may use on his or her own, assuming the
presence of proper training and supervision. For example, handheld data collection devices or lab
equipment.
Shared Space: Access to research space that a Core user may use to perform studies. For example,
access to space for use in recruiting into or performing clinical or behavioral studies.
Materials: Portable items given to Core Users. For example, tissue samples, chemicals, labware, and/or
documents.
Services:
Developmental Services: Activities that Core staff undertake in order to develop a greater capacity for
assisting Core Users in the future. For example, optimization, standardization, and validation of novel
assays.
Requested Services: Activities that Core staff undertake at the request of a Core User. For example,
performing an already standardized assay.
Training: Imparting knowledge or a skill to a Core User that s/he may later use on his or her own. For
example, teaching someone how to use a piece of equipment, design a study, perform an assay, or do a
power analysis
Other: Other value added activities not covered above. For example, community outreach.
Value Added Example: A well-written value added example has three components:
1. A brief description of the situation/achievement to which the CFAR added value
2. A concrete description of the action taken / resources provided
3. The outcome resulting from CFAR’s contribution
Value Added examples are formatted in this way:
[Situation]
Rev 10/24/14
2
 [Action taken] [Outcome]
Rev 10/24/14
3
USING THIS GUIDANCE
For the purposes of this Appendix Guidance, examples of completed tables are provided as they might have
been compiled by a hypothetical “Urban University CFAR” for submission to NIH for their current reporting
period, which covers Urban CFAR’s Project Year YR10 (8/1/14 – 7/31/15).
The complete list of YR10 Urban CFAR users who appear in this guidance is provided below. For each
individual listed this includes: PI/PD name, where s/he is from, what CFAR User Categories s/he falls into,
what roles s/he held within the CFAR, and the CFAR Cores and SWGs that provided support of some sort for
him or her during the current reporting period.
All Urban CFAR Users in YR10
Name
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
Location
Baba, Ali
Badenov, Boris
Banzai, Buckeroo
Beckett, Sam
Boop, Betty
Bullfrog, Jeremiah W.A.
Calvin, Susan
Coyote, Wile E.
Croft, Lara
Durga, Devi
Doolittle, John
Explorer, Dora T.
Falken, Stephen
Hackwrench, Gadget
Jones, Indiana
Mephisto, Alphonse
Moreau, N.F.N.
Neutron, Jimmy
Omega, Zenith
Scully, Dana
Shango, Bumba
Stein, Francis N. (Frank)
Who, Doctor
Urban U
Urban U
Urban U
Urban U
Suburban CFAR
Urban U
Urban U
Suburban CFAR
Urban U
YRGC, Chennai
Urban U
Urban U
Urban U
Urban U
Urban U
Urban U
Urban U
Rural CFAR
Urban U
Area 51 D-CFAR
KwaZulu-Natal
Urban U
Urban U
Categories
Roles*
2,5,6
2
1
1
3,
1
1
4,5
1,5
4,5,6
3,5
3,5
3
4,5, 6
1
2,5
2,5
1
1
3
4,5,6
2
2,5
CU
CU
BDC,CU
CU
CU
CU
CD,CU,SD
CU
CU
CU
CU
CU
CU
CU
BDC,CU
CU,SM
CU,SM
BDC,CU
BDC,CU
SM
CU
CU
CU
CORES
B
X
C
D
X
X
X
X
H
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
SWG
F
X
X
X
X
X
X
X
X
X
X
X
X
4
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
2
X
X
X
X
X
X
*CD=Core Director, CU=Core User, SD=SWG Director, SM=SWG Member, BDC=Big Dogs Council
Rev 10/24/14
1
X
X
X
J
X
X
X
X
X
APPENDICES TABLE OF CONTENTS
The purpose of the Appendices Table of Contents is to help readers navigate to specific sections within the
Appendices. When constructing your Table of Contents, follow the format provided below.
Appendix:
A
A.1: [XXXX] FRB projects supported by the CFAR.............................................................................. 2
A.2: Other YR[26] NIH-funded projects supported by the CFAR ...........................................................
B
B.1: External Advisory Board Report .....................................................................................................
B.2: Internal Advisory Board Report .....................................................................................................
C
C.1: All Core B activities ........................................................................................................................
C.2: New Awards: Abstracts, progress reports, and regulatory documents ............................................
C.3: Active Projects: Progress reports and regulatory documents .........................................................
C.4: Newly Completed Projects: Summary reports and regulatory documents ......................................
D
D.1: Core [X] ([Name]) Utilization Table and Other Significant Activities ................................................
D.2: Core [X] ([Name]) Utilization Table and Other Significant Activities ................................................
Note: Each Science Core should appear in its own appendix subsection.
E
E.1: SWG [#] ([Name]) Membership Table ............................................................................................
E.2: SWG [#] ([Name]) Membership Table ............................................................................................
Note: Each SWG should appear in its own appendix subsection.
Rev 10/24/14
5
APPENDIX A: Support for NIH-funded Projects
A.1
PURPOSE: To document the support that CFAR Cores provided to projects appearing on the FRB.





Label the table with the NIH fiscal year whose FRB information is being reported. (See example below)
Include one row on the table for each row appearing on the “ALLOW” tab of the most recent FRB report Excel sheet
o include those projects for which no Core assistance was provided
Do NOT submit the actual FRB Excel spreadsheet with your report
For each separate project list the Core(s) that provided a specific type of support for the project:
consultation (C), equipment or space (E/S), materials (M), services (S), training (T) or other (O) – for that project.
Edit the standard “Roles” legend to include roles that are specific to your CFAR
[Example from Urban CFAR’s appendix A
2013 FRB “Allow” Tab Projects Supported by the CFAR
PI
Roles*
Banzai,
Buckeroo
Beckett,
Sam
Bullfrog,
Jeremiah
W. A.
Croft, Lara
CU,
BDC
CD,
CU
CU
Omega,
Zenith
CU,
BDC
Categories
1
1
1
CU
1
1
Grant Title
Giraffe models of HIV-associated head and neck
cancers
Quantum leap: Time travel as a novel HIV
prevention strategy
Joy to the fishes in the deep blue sea: The
development of a Zebrafish dendritic cell model in
HIV
Archeological evidence of HIV in Egyptian tombs
Aerosolized delivery of a cure for HIV
* CD=Core Director, CU=Core User, BDC=Big Dogs Council
Rev 10/24/14
6
Grant #
P01
CA555121
R29
MH010101
R37
CA010000
R23
AI555555
R01
DA54321
C
H
CORES THAT PROVIDED SUPPORT
E/S
M
S
T
O
D
F
C
F
C
H
H
H
J
J
J
C,D
F,J
H
F,H,2
H
2
A.2
PURPOSE: To document the support that CFAR Cores provided to projects NOT appearing on the most recent FRB.



Include a row for each NIH-funded project supported by the CFAR in the current reporting period, that does not appear in Appendix A.1
o Do NOT include NIH-funded projects for which no CFAR Core assistance was provided
For each separate project list the Core(s) that provided a specific type of support for the project:
consultation (C), equipment or space (E/S), materials (M), services (S), training (T) or other (O) – for that project.
Edit the standard “Roles” legend to include roles that are specific to your CFAR (see example below)
[The example table below is not comprehensive for the Urban CFAR’s Y10 reporting period]
Other NIH-funded Projects Supported by the CFAR
Name
Roles*
Badenov,
Boris
Baba, Ali
CU,
BDC
Banzai,
Buckeroo
Calvin,
Susan
CU,
BDC
CU,
CD,
SD
CU
Doolittle,
John
Explorer,
Dora
Hackwrench,
Gadget
Jones,
Indiana
Mephisto,
Alphonse
Neutron,
Jimmy
Categories
2
2,5
CU
CU
BDC,
CU
CU,
SM
BDC,
CU
1
1
3,5
3,5
4,5,6
1
2,5
1
Grant Title
Using moose and squirrel to detect HIV in former
Soviet countries
Are opened sesames a magic bullet for AIDS-related
cancer control?
Innovative research housing for a griffin colony
Environmental obstacles to the use of sentient
robots to provide HIV care in jungle and dessert
settings
Increasing Recruitment of Female Centaurs (“FeMares”) in HIV Research
Where in the World is HIV?
New technologies for a rapid HIV test based on
measuring aura color
Arc of the covenant: Histo-religious distinctions in
responses to HIV and AIDS
Nutritional Requirements of Vegan-Carnivore
Chimera
Adapting alien technology for use in cloning CD4+
effector memory T cells
* CD=Core Director, CU=Core User, SD=SWG Director, BDC=Big Dogs Council
Rev 10/24/14
7
Grant #
D43
TW555121
NCI Admin
Supplement
C06
0D018248
Core B
Core B
Core B
NCCAM
Admin Sup.
R36
MD200002
Core B
R21
AI989898
CORES/SWGs THAT PROVIDED SUPPORT
C
E/S
M
S
T
O
H, C
H
B
F
J
J
J
J
1
B
J
B, C
D
B
C
F
D
H
F
F
H
H
F
J
B, H
F, J
J
H
B, H
B
H
B
B
B
H
Program Director/Principal Investigator (Last, First, Middle):
Curran, James W.
Appendix B: Advisory Committee Findings
The purpose of Appendix B is to describe the strategic planning recommendations that have been provided to
your CFAR by committees established specifically for that purpose.
Appendix B.1
Appendix B.1 should include the report from the most recent meeting of your External Advisory Board, if one
has been held since the last progress report was submitted.
If no meeting of the External Advisory Board was held in the current reporting period say so here.
Do not include meeting agendas or materials provided to Advisory Board members
Appendix B.2
The purpose of Appendix B.2 is to describe the recommendations and actions arising from any major meetings
of your Internal Advisory Board (IAB) or other internal CFAR committees that were established specifically to
provide scientific review and advice to the CFAR.
If no IAB meetings were held in the current reporting period say so here.
Do not include meeting agendas or materials provided to advisory committee members
PHS 398/2590 (Rev. 06/09)
Page
8
Continuation Format Page
Appendix C.1 – All Core B Activities
PURPOSE: To provide the specifics for each funding application received by Core B in response to the mechanisms described in the
“Application Summary Table” contained in the Core B narrative.
The example tables below are provided to illustrate the type of information you would provide for some of the mechanisms that were used in the
examples provided in the Core B narrative Guidance. It is not expected that CFARs will provide these exact funding mechanisms.
ADMINISTRATIVE SUPPLEMENT APPLICATIONS AND AWARDS
The table below should list administrative supplements received since the last progress report was submitted. For each project listed below
provide, in Appendix C.2.1, an abstract, progress report, and current copies of regulatory approval letters (IRB, IACUC), as applicable.
ADMINISTRATIVE SUPPLEMENTS: NEWLY FUNDED
PD(s)
Category
Mentor
Date
Awarded
Baba, Ail
2,5,6
Banzai
08/01/14
Buckeroo
Institute
Title
NCI
Are open sesames a magic bullet for AIDS-related
cancer control?”
Regulatory
Permissions
IRB
The table below should list administrative supplement applications submitted to NIH that were not funded and describe what actions were
subsequently taken.
ADMINISTRATIVE SUPPLEMENT APPLICATIONS: NOT FUNDED
Applicant Category
Applied
Title
The use of artificial intelligence in HIV prevention
Falken,
3
11/1/14
Stephen
Outcome
Research hypothesis is being rethought
under mentor’s supervision (Alan Turing)
The table below should list administrative supplements that have already been reported in a previous progress report and are still active. For
each project listed below provide, in Appendix C.3.1, a progress report and current copies of regulatory approval letters (IRB, IACUC), as
applicable. Also provide, in Appendix C.5, updated outcomes to date via the NIH’s Cumulative Outcomes Summary.
ADMINISTRATIVE SUPPLEMENTS: ACTIVE
PI(s)
Category
Date
Institute
Awarded
Shango, Bumba 4,5,6
10/01/13
NIAID
& Devi, Durga
4,5,6
9
Title
Regulatory Permissions
South-South partnerships in AIDS vaccine research
International clearance
The table below should list administrative supplements that finished their funded activities after the last progress report was submitted. For
each project include, in Appendix C.4.1, a progress report and copies of any necessary regulatory approvals (IRB, IACUC) that were current
at the time funded activities finished. Also provide, in Appendix C.5, updated outcomes to date via the NIH’s Cumulative Outcomes
Summary.
ADMINISTRATIVE SUPPLEMENTS: NEWLY COMPLETED
PI(s)
Category
Date
Institute
Title
Completed
New technologies for a rapid HIV test based on measuring aura
Hackwrench,
4,5,6
07/15/14
NCCAM
color
Gadget
Regulatory Permissions
None required
INTERNAL FUNDING APPLICATIONS AND AWARDS
The table below should list internal awards given since the last progress report was submitted. For each project listed below provide, in
Appendix C.2.[#], an abstract, progress report, and current copies of regulatory approval letters (IRB, IACUC), as applicable.
INTERNAL AWARDS: NEWLY FUNDED
PI(s)
Category
Mentor
Doolittle,
John
Moreau,
N.F.N.
3,5
2,5
Buckeroo
Banzai
N/A (Category
2 applicant)
Date
Awarded
Mechanism
Title
Regulatory
Permissions
08/08/14
Microgrant
Increasing Recruitment of Female Centaurs (“Fe-Mares”)
in HIV Research
IRB, IACUC
01/15/15
CFAR03
(Y10A)
Mouse/Macaque Models for AIDS Vaccine Studies
IACUC
The table below should list applications received since the last progress report was submitted that were not funded and describe what
actions were subsequently taken.
INTERNAL APPLICATIONS: NOT FUNDED
Applicant
Category
Date Applied
Hound,
Basset
Farnsworth,
Hubert J.
(Mars U)
Mechanism
2
11/1/14
Opportunity
Award
4
11/1/14
SWG 2 Seed
Grant
Title
Development of a Robust, Sensitive Microsphere-based
Assay to Quantify FIV in Transgenic Cats
Outcome
Futurama: Cloning People as Old as Me who have the
letters “H” “I” and “V” in their Name
No resubmission of this
proposal will be accepted
Revising for resubmission
The table below should list projects that have already been reported in a previous progress report and are still active. For each project listed
below provide, in Appendix C.3.[#], a progress report and current copies of regulatory approval letters (IRB, IACUC), as applicable. Also
provide, in Appendix C.5, updated outcomes to date via the NIH’s Cumulative Outcomes Summary.
INTERNAL AWARDS: ACTIVE
PI(s)
Category
Mechanism
Explorer,
CFAR03
3,5
Dora T
(Y09B)
Title
Regulatory Permissions
Where in the World is HIV?
International clearance
10
The table below should list projects that finished their funded activities after the last progress report was submitted. For each project include,
in Appendix C.4.[#], a progress report and copies of any necessary regulatory approvals (IRB, IACUC) that were current at the time funded
activities finished. Also provide, in Appendix C.5, updated outcomes to date via the NIH’s Cumulative Outcomes Summary.
INTERNAL AWARDS: NEWLY COMPLETED
PI(s)
Category
Date Completed
Mephisto,
10/01/14
2,5
Alphonse
Mechanism
CFAR03
(Y08A)
Title
Regulatory Permissions
Nutritional Requirements of Vegan-Carnivore Chimera
IACUC, IRB
OTHER CORE B ACTIVITIES
The purpose of this subsection is to summarize any other significant activities that Core B engaged in since the last report. The table or
tables used to report the information may be formatted in any way that will help you summarize those Core B activities that provided the
most value added. Do not attach flyers or RFA announcements
Conference Support
Category
Name
Baba, Ali
2,5,6
Croft, Laura:
1,5
Explorer, Dora T: 3,5
Application Support
Category
Name
CTSI
N/A
Coyote, Wile E.
4,5
Activity
Travel award; arranged for feedback on APHA conference oral presentation by members of SWG 2
Travel award; arranged for internal review of CROI abstract prior to (successful) submission
Travel award: poster design tutorial and printing for presentation at APHA (Poster: “Where in the World is HIV?”)
Activity
Review Committee for Core B helped review CTSI pilot project applications.
Solicited external reviews of draft R21 application.
Mentoring Activities
Mentee
Mentor
Frequency of Contact
Activities
Baba, Ali
Angelika Pickes,
Once a month
Provided advice on
assays
Explorer, Dora T
Christopher
Columbus
Devi, Durga & Shango,
Bumba
Indiana Jones
Met weekly during
application development,
monthly since then
Bi-monthly, via Skype
Introduced to research
mentor and proposed
foreign collaborators
Ongoing research
mentoring for NIH
administrative
supplement award
11
Other Cores/SWGs
Involved
Virology Core
Clinical and
Immunology Cores
Biostatistics and
Virology Cores
Outcome
Introduced to the Virology
Core for development of
new assay
Supplement application
submitted (funded),
South-South partnership
established; All Urban
University-based training
complete; enrollment
targets met
Appendix C.2 – New Awards
The purpose of this appendix is to succinctly describe each newly-funded project reported in Appendix C.1.
Follow the required format provided below.
Organization:
 Group reports by funding mechanism, with NIH supplements listed first (C.2.1).
 Provide a separate subsection (C.2.2; C.2.3 etc) for each internal mechanism.
 Within subsections, alpha order by contact PI’s last name.
Header: Follow the format provided in the examples below
 Not every project may have a mentor (e.g. senior faculty being brought into AIDS)
 Regulatory permission choices are: None, IRB, IACUC, NIH (Medical and/or International)
Abstract: Follow the same rules as for an NIH application abstract/project summary. Specifically:
 Limit length to 30 lines or less of text
 Include the project’s broad, long-term objectives and specific aims
 Include a description of the research design and methods for achieving the stated goals
 Do NOT include proprietary or confidential information, or trade secrets
 Write in plain language, so even a non-scientists can understand the importance of the project
Progress Report section:
 Limit length to amount of page remaining below completed header and abstract
 Include any information not being collected in the online NIH Cumulative Outcomes Summary – e.g.
oral and poster conference presentations
Regulatory Permissions section:
 After the progress report, attach current copies of all permission letters listed in the report header (IRB,
IACUC) that have been received by time of report submission.
 Indicate regulatory permissions that have not yet been received.
C.2.1: Newly Funded NIH Administrative Supplements
Ali Baba, PhD
Are Open Sesames a Magic Bullet for AIDS-related Cancer Control?
Funded Activities Completed: N/A
Award: $75,000
Mechanism: NCI Administrative Supplement
Mentor(s): Buckeroo Bonzai
Project Period: 08/01/14 – 07/31/15
Regulatory Permissions Required: IRB, NIH Medical Approval
Date Report Received: 11/01/14
Abstract:
[see instructions above]
Progress Report:
This study is still in the preparation period.
Regulatory Approvals:
See attached IRB approval. NIH medical approval is still in process
[Imagine attached copy of IRB approval letter here]
NOTE: Although NIH medical approval is required do not attach copies of NIH medical checklist, protocol,
emails between CFAR and NIH, or any other materials including targeted/planned enrollment tables.
12
C.2.2: Newly Funded CFAR03 Pilot Projects
N.F.N. Moreau, MD, PhD
Mouse-Macaque Models for AIDS Vaccine Studies
Funded Activities Completed: N/A
Award: $40,000
Mechanism: standard CFAR03 (Y10A)
Mentor(s): None (Category 2)
Project Period: 01/15/15 – 01/14/16
Regulatory Permissions Required: IACUC
Date Report Received: 02/15/15
Abstract:
[see instructions above]
Progress Report:
This study is still in the preparation phase.
Regulatory Approvals:
None to attach. IACUC approval In still in process.
C.2.3: Newly Funded Microgrants
John Doolittle, MD
Increasing Recruitment of Female Centaurs (“Fe-Mares”) in HIV Research
Funded Activities Completed: N/A
Award: $2,000
Mechanism: Microgrant
Mentor(s): Buckeroo Banzai
Project Period: 08/08/14 – 02/07/15
Regulatory Permissions Required: IRB, IACUC
Date Report Received: 10/15/14
Abstract:
[see instructions above]
Progress Report:
This study is still in the preparation phase.
Regulatory Approvals:
See attached IRB approval. IACUC approval is still in process
[Imagine copy of IRB approval letter attached here]
13
Appendix C.3 – Active Awards
The purpose of Appendix C.3 is to provide a succinct update on progress made by active projects (including
those operating under no cost extensions) since submission of the last progress report.
Do not provide progress reports for any project completely external to the CFAR.
For example, projects funded by another organization for which Core B provided study section assistance
may be described as a community outreach initiative in “Other Core B Activities” or “Other Key
Achievements” but reports for those projects should not be included here.
Organization:
 As in Appendix C.2, group reports by funding mechanism, with NIH supplements listed first (C.3.1).
 Provide a separate subsection (C.3.2; C.3.3 etc) for each internal mechanism.
 Within subsections, alpha order by contact PI’s last name.
Header: Follow the format provided in the examples below
 Not every project may have a mentor (e.g. senior faculty being brought into AIDS)
 If project is operating under a No Cost Extension, use Project Period format as in Shango & Devi
example below
 Regulatory permission choices are: None, IRB, IACUC, NIH (Medical and/or International)
Progress Report section:
 Limit length to amount of page remaining below completed header (i.e., no report to exceed one page)
 Tables are permitted but do not include graphs, pictures, or articles in reports.
 Only include information that is new since the last progress report was submitted
 Include any information not being collected in the online NIH Cumulative Outcomes Summary – e.g.
information about oral and poster conference presentations
Regulatory Permissions section:
 After the progress report, attach current copies of permission letters listed in the report header (IRB,
IACUC)
C.3.1: Active NIH Administrative Supplements
Bumba Shango, PhD & Durga Devi MD
South-South Partnerships in AIDS Vaccine Research (NIAID)
Funded Activities Completed: N/A
Award: $125,000
Mechanism: NIAID Administrative Supplement
Mentor(s): Indiana Jones
Project Period:
Original: 10/01/13 – 9/30/14
NCE: 10/01/13 – 9/30/15
Regulatory Permissions Required: NIH International Clearance
Date Report Submitted: 9/15/14
Progress Report:
This project has just received international clearance. We are awaiting receipt of a revised NGA from the NIH
CFAR to begin funded activities.
Regulatory Approvals:
N/A
Note: There are no attached regulatory approvals as neither IRB nor IACUC is required for this study.
Although NIH international clearance is required do not attach copies of international checklist, emails
between CFAR and NIH, revised NOA, or any other materials including targeted/planned enrollment tables.
14
C.3.2: Active CFAR03 Pilot Projects
Dora T. Explorer, PhD
Where in the World is HIV?
Date Funded Activities Completed: N/A
Award: $40,000
Mechanism: Co-funded CFAR03 (Urban University Dept. of Global Health)
Mentor(s): Christopher Columbus
Project Period: 08/15/14 – 08/14/15
Regulatory Permissions Required: NIH International Clearance
Date report received: 8/15/14
Progress Report:
[Insert here]
Regulatory Approvals:
International clearance documents on file at NIH
Appendix C.4 – Newly Completed Projects
The purpose of Appendix C.4 is to provide a summary report for projects that have completed funded activities
since submission of the last progress report.
Do not provide reports for any project completely external to the CFAR.
For example, projects funded by another organization for which Core B provided a poster design tutorial
may be described in “Other Core B Activities” but should not be included here.
Organization:
 As in Appendix C.2, group reports by funding mechanism, with NIH supplements listed first (C.4.1).
 Provide a separate subsection (C.4.2; C.4.3 etc) for each internal mechanism.
 Within subsections, alpha order by contact PI’s last name.
Header: Follow the format provided in the examples below
 Not every project may have a mentor (e.g. senior faculty being brought into AIDS)
 If project included a No Cost Extension, use Project Period format as in Mephisto example below
 Regulatory permission choices are: None, IRB, IACUC, NIH (Medical and/or International)
Summary Report section:
 Limit length to amount of page remaining below completed header (i.e., no report to exceed one page)
 Tables are permitted but do not include graphs, pictures, or articles in reports.
 Briefly summarize project activities and outcomes
 Include any information not being collected in the online NIH Cumulative Outcomes Summary – e.g.
information about oral and poster conference presentations
Future Plans section
 Limit length of “Future Plans” section plus “Value Added” section plus “Regulatory Permissions” header
and descriptive text to one page total
 Describe the PI’s next steps for use of the findings and how this project will lead to future NIH funding
Value Added by the CFAR section
 See comment about Value Added section length in “Future Plans” instructions above
 Describe why the PI is happy to have received the money – i.e. what she or he was able to accomplish
that they wouldn't have been able to had it not been for the award. For example, "Because of the
Developmental Core award Dr. X …. " or "If it hadn't been for the Developmental Core award Dr. X
would not have been able to …."
15
Regulatory Permissions:
 At the end of the report attach copies of permission letters listed in the report header (IRB, IACUC)
documenting that regulatory permissions were current at the time funded activities completed
C.4.1: Newly Completed NIH Administrative Supplements
Gadget Hackwrench, PhD
New technologies for a rapid HIV test based on measuring aura color
Funded Activities Completed: 07/15/14
Award: $50,000
Mechanism: NCCAM Administrative Supplement
Mentor(s): Zenith Omega
Project Period: 08/01/13 – 07/31/14
Regulatory Permissions Required: None
Date report received: 09/01/13
Summary Report:
[insert report here]
Future Plans:
[insert report here]
Value Added by the CFAR:
[insert report here]
Regulatory Permissions:
N/A
C.4.2: Newly Completed CFAR03 Pilot Projects
Alphonse Mephisto, MD, PhD
Mouse/Macaque Chimeras: The Next Generation Model
Funded Activities Completed: 10/01/14
Award: $40,000
Mechanism: Standard CFAR03
Mentor(s): None (Category 2)
Project Period:
Original: 11/01/12 – 10/31/13
NCE: 11/01/12 – 10/31/14
Regulatory Permissions Required: IACUC
Date report received: 11/15/14
Summary Report:
[insert report here]
Future Plans:
[insert report here]
Value Added by the CFAR:
[insert report here]
Regulatory Permissions:
See attached IACUC letter
[Imagine IACUC letter attached here]
16
NOTE
Core B Awards Outcome Summary, 2000 – current
The NIH Google Document (Excel template) is no longer available and is being replaced by a secure
website interface that will be used to directly input information. Information in that website will be
available online to NIH CFAR readers. No outcome summary report needs to be printed and included
here.
17
Appendix D – CFAR Science Core Activities
The purpose of this appendix is to describe the support provided for CFAR- and NIH-funded projects and other key activities of the Core.
 Report information for each Science Core in a separate Appendix (D.1, D.2, D.3, etc).
 Divide information into two tables: 1) Support for NIH-Funded Projects; 2) Other Significant Activities.
 The “% Use” column for the two tables should cumulatively equal 100%
 List Core B projects first, followed by NIH Admin Supplements, followed by NIH awards
 Put the names of first time core users in italicized font; put NIH grant numbers appearing on FRB in bold face font
 Under “Core Services Provided” Label the Value Added Activity by type and then provide enough detail to make it clear how the user
benefitted from their interaction with the Core (see Core Support legend beneath example Table #1 below)
Appendix D.6 – Core H
Core H Utilization Table: Support for Core B- and NIH-Funded Projects
Investigator (location)
“Core B” or NIH Title of Project
Category
Collaborator (location)
Grant Number
Calvin, Susan (Urban U) &
Boop, Betty (Suburban
CFAR)
Explorer, Dora T.
(Urban Univ)
Mephisto, Alphonse
(Urban Univ)
Hackwrench, Gadget
(Urban Univ)
Badenov, Boris
(Urban Univ)
Banzai, Buckeroo
(Urban Univ.)
Beckett, Sam
(Urban Univ)
Bullfrog, Jeremiah W.A.
(Urban Univ)
Jones, Indiana
(Urban Univ)
Neutron, Jimmy
(Rural CFAR)
Omega, Zenith
(Urban Univ)
Core B
Environmental obstacles to the use of
sentient robots to provide HIV care in
jungle and dessert settings
Core B
Where in the World is HIV?
Core B
Nutritional Requirements of
Vegan-Carnivore Chimera
New technologies for a rapid HIV test
based on measuring aura color
Using moose and squirrel to detect
HIV in former Soviet Block countries
Giraffe models of HIV-associated
head and neck cancers
Quantum leap: Time travel as a novel
HIV prevention strategy
Joy to the fishes in the deep blue sea:
The development of a Zebrafish
dendritic cell model in HIV
Arc of the covenant: Histo-religious
distinctions in responses to HIV and
AIDS
Adapting alien technology for use in
cloning CD4+ effector memory T cells
Aerosolized delivery of a cure for HIV
1
3,5
2,5
4,5,6
2
1
1
NIH Admin Supp
D43 TW555121
P01 CA555121
R29 MH010101
R37 CA010000
1
R36 MD200002
1
1
1
R21 AI989898
R01 DA54321
18
Core Services Provided
Space: Provided use of BSL2 facility
Consulting: Advice on study design
Services: cell sorting
Consulting: Advice on study design
% Use
3
3
<1
Training: Use of flow cytometer
Equipment: Access to flow cytometer
Materials: Provided assays and
specimens
Consulting: Advice on study design
4
12
Training: Use of flow cytometer
<1
Services: Dendritic cell sorting
13
Consulting: Advice on study design
<1
Training: BSL2 protocols
Services: Provided tetramer staining
Space: Access to a BSL3 facility
Services: Use of BSL3 staff
10
10
9
Core H: Other Significant Activities
Type
Activity
Training
Services
Other
% Use
Provided training for 10 labs on flow cytometer use and training for 5 labs on BSL3 protocols
Developed 18 novel assays to increase capacity of the Core
Performed flow assays for CDC-funded project (Disease Surveillance in Parallel Universes; Dr. Who, PI) that enabled first ever
research collaboration between Urban University CFAR scientists and CDC scientists
15
20
<1
The purpose of the table above is to describe other activities that EITHER took significant amounts of Core time OR provided significant value
added. Format table as needed to present the information as succinctly and quantitatively as possible
The “% Use” column for Tables 1 and 2 should cumulatively equal 100%
19
Appendix E
The purpose of Appendix E is to describe the individuals who belong to each of the CFAR’s Scientific Working Groups (SWGs).
Bear in mind that a central purpose of the SWG concept is to turbocharge HIV/AIDS research by including investigators who can contribute
expertise from other fields, to support junior and NIH New Investigators, and to bring together a broad array of expertise and interests. Use this
roster to document progress in achieving this purpose.




Use column 2 (“New to SWG”) to identify members who have joined the SWG since the previous year
Use column 3 (“Outside Expertise”) to identify members who are primarily contributing expertise that is outside of the field of HIV/AIDS
Use column 4 (“Categories”) to identify unfunded (Category 4) or NIH new investigators (Category 3)
Provide enough detail on research interests to make it clear how their research will facilitate the work of the SWG
Appendix E.1
SWG 1: Artificial, Mythic, and Extraterrestrial Life Forms
First established: 11/01/2013
Membership roster as of: 05/25/14
Name
(Location)
New to
SWG
Outside
Expertise
Susan Calvin
(DIRECTOR)
(Urban U)
Alphonse
Mephisto
(Urban U)
N.F.N.
Moreau
(Urban U)
Dana Scully
(Area 51 DCFAR)
Frank Stein
(Urban U)
Categories
Primary Research Area
Involvement with the SWG
1
Application of HIV immunology to
artificial life forms
SWG Director. Helping to identify potential coinvestigators for P30 application currently under
discussion
Organizing activities of the SCREAM journal club
to assist in locating pertinent literature; will serve
as Co-investigator on R01 application under
development
Providing SCREAM Center research field site (at
his undisclosed island location)
2,5
X
X
X
X
X
2,5
The use of genetic engineering to
increase innate and acquired
resistance to HIV infection
Development and use of HumanAnimal chimera in clinical
research
Clinical care of extraterrestrials
3
2
Communicable diseases in
mermaids
20
Gave research presentation at SWG meeting;
serving as a co-investigator in upcoming R01
application being organized by the SWG
Applying for CFAR03 seed grant funding through
the SWG to expand current research on STDs
(Sea-transmitted Diseases) to include AIDSassociated malignancies